CERT (Certara, Inc. Common Stock)
Insider Trading Activity
Every open-market purchase and sale reported by CERT officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-02 | Faiz Mohammed | Interim CFO | A | — | — |
| 2026-06-02 | Daniel Corcoran | SVP and General Counsel | MIXED | — | — |
| 2026-06-02 | Rona Anhalt | Chief Human Resources Officer | MIXED | — | — |
| 2026-05-15 | MATTHEW M WALSH | Director | M | — | — |
| 2026-05-15 | Rosemary A Crane | Director | M | — | — |
| 2026-05-15 | Nancy Killefer | Director | M | — | — |
| 2026-05-15 | JAMES E CASHMAN III | Director | M | — | — |
| 2026-05-15 | Arjun Bedi | Director | M | — | — |
| 2026-05-15 | ERAN BROSHY | Director | M | — | — |
| 2026-05-15 | John V W Reynders | Chief Financial Officer | M | — | — |
| 2026-05-15 | Cynthia Collins | Director | M | — | — |
| 2026-05-13 | John E Gallagher | Chief Financial Officer | MIXED | — | — |
| 2026-05-13 | Daniel Corcoran | SVP and General Counsel | MIXED | — | — |
| 2026-05-13 | Jon Matthew Resnick | Chief Executive Officer | MIXED | — | — |
| 2026-05-13 | Rona Anhalt | Chief Human Resources Officer | MIXED | — | — |
| 2026-05-13 | Leif E Pedersen | PRESIDENT, CHIEF COMMERCAL OFF | MIXED | — | — |
| 2026-05-13 | Robert Aspbury | PRESIDENT, PREDICTIVE TECH | MIXED | — | — |
| 2026-04-03 | Rona Anhalt | Chief Human Resources Officer | MIXED | — | — |
| 2026-04-03 | Robert Aspbury | PRESIDENT, PREDICTIVE TECH | MIXED | — | — |
| 2026-04-03 | John E Gallagher | Chief Financial Officer | MIXED | — | — |
| 2026-04-03 | Daniel Corcoran | SVP and General Counsel | MIXED | — | — |
| 2026-04-03 | Adrian McKemey | President, Drug Dev. Solutions | MIXED | — | — |
| 2026-04-03 | Leif E Pedersen | PRESIDENT, CHIEF COMMERCAL OFF | MIXED | — | — |
| 2026-03-02 | Arjun Bedi | Director | A | — | — |
| 2025-11-12 | William F Feehery | CHIEF EXECUTIVE OFFICER | Buy | — | — |
| 2025-09-11 | Leif E Pedersen | PRESIDENT, CHIEF COMMERCAL OFF | Sell | — | — |
| 2025-06-02 | Daniel Corcoran | SVP and General Counsel | MIXED | — | — |
| 2025-06-02 | Rona Anhalt | Chief Human Resources Officer | MIXED | — | — |
| 2025-05-22 | William F Feehery | CHIEF EXECUTIVE OFFICER | A | — | — |
| 2025-05-22 | Robert Aspbury | PRESIDENT, PREDICTIVE TECH | A | — | — |
| 2025-05-22 | John E Gallagher | Chief Financial Officer | A | — | — |
| 2025-05-22 | Adrian McKemey | President, Drug Dev. Solutions | A | — | — |
| 2025-05-22 | Leif E Pedersen | PRESIDENT, CHIEF COMMERCAL OFF | A | — | — |
| 2025-05-22 | Daniel Corcoran | SVP and General Counsel | A | — | — |
| 2025-05-22 | Rona Anhalt | Chief Human Resources Officer | A | — | — |
| 2025-05-22 | ERAN BROSHY | Director | M | — | — |
| 2025-05-22 | JAMES E CASHMAN III | Director | M | — | — |
| 2025-05-22 | Cynthia Collins | Director | M | — | — |
| 2025-05-22 | Rosemary A Crane | Director | M | — | — |
| 2025-05-22 | Nancy Killefer | Director | M | — | — |
| 2025-05-22 | John V W Reynders | Director | M | — | — |
| 2025-05-22 | MATTHEW M WALSH | Director | M | — | — |
| 2025-04-03 | William F Feehery | CHIEF EXECUTIVE OFFICER | MIXED | — | — |
| 2025-04-03 | John E Gallagher | PRESIDENT, CHIEF COMMERCAL OFF | MIXED | — | — |
| 2025-04-03 | Leif E Pedersen | PRESIDENT, CHIEF COMMERCAL OFF | MIXED | — | — |
| 2025-04-03 | Robert Aspbury | PRESIDENT, PREDICTIVE TECH | MIXED | — | — |
| 2024-10-18 | John V W Reynders | Director | A | — | — |
| 2024-10-08 | PATRICK F SMITH | PRESIDENT, DRUG DEV SOLUTIONS | Sell | — | — |
| 2024-10-07 | PATRICK F SMITH | PRESIDENT, DRUG DEV SOLUTIONS | MIXED | — | — |
| 2024-09-10 | Leif E Pedersen | PRESIDENT, CHIEF COMMERCAL OFF | Sell | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | 10%+ Owner | 35,958,939 | — |
| — | CHIEF EXECUTIVE OFFICER | 2,360,769 | — |
| — | Director | 906,115 | — |
| — | Director | 621,143 | — |
| — | CHIEF FINANCIAL OFFICER | 522,895 | — |
| — | Director | 484,197 | — |
| — | PRES., REGULATORY & ACCESS | 394,764 | — |
| — | PRESIDENT, PREDICTIVE TECH | 324,393 | — |
| — | PRESIDENT, INTEGRATED DRUG DEV | 316,210 | — |
| — | CHIEF STRATEGY & MARKETING | 248,577 | — |
| — | Director | 213,316 | — |
| — | See Remarks | 173,564 | — |
| — | SVP AND GENERAL COUNSEL | 167,750 | — |
| — | PRESIDENT, CHIEF COMMERCAL OFF | 113,744 | — |
| — | Chief Financial Officer | 74,732 | — |
| — | Chief Executive Officer | 59,766 | — |
| — | Director | 51,846 | — |
| — | Director | 51,846 | — |
| — | Director | 50,708 | — |
| — | PRESIDENT, DRUG DEV SOLUTIONS | 50,091 | — |
| — | Director | 45,672 | — |
| — | Director | 42,000 | — |
| — | Chief Financial Officer | 26,466 | — |
| — | CHIEF HUMAN RESOURCES OFFICER | 25,684 | — |
| — | SVP and General Counsel | 25,050 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the CERT quote page; the site-wide leaderboard is on the insider transactions hub.